FDA Approves New Manufacturing Facility in Clearwater, Florida for Sacrosidase, Active Ingredient of Sucraid® (sacrosidase) Oral Solution, for the Treatment of Congenital Sucrase-Isomaltase Deficiency
October 2, 2018, Vero Beach, FL – Today QOL Medical, LLC announced that the U.S. Food and Drug Administration (FDA) has approved the company’s wholly owned manufacturing facility in Clearwater, Florida to manufacture sacrosidase, the drug substance used to make Sucraid® (sacrosidase) Oral Solution. The Sucraid® drug shortage has been resolved, and